Findings

What do systematic reviews say?

5 questions · 5 findings · 3 reviews · Musculoskeletal

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 40%Low 2 · 40%Moderate 0 · 0%High 1 · 20%

Tricyclic antidepressants vs control

Withdrawals due to adverse events · patients with pain management in rheumatoid arthritis

It is very uncertain whether tricyclic antidepressant changes number of Withdrawals due to Adverse Events patient interview compared with control (very low certainty).

1 finding from 1 review

Antidepressants for pain management in rheumatoid arthritis 2011 · Cochrane Headline outcomes only
RR 0.98 [0.59, 1.64]
6 studies · 455 participants
Very low

Intermittent/cyclic etidronate 400 mg/day vs placebo

Withdrawals due to adverse events · postmenopausal women with a higher risk for fracturesa

It is very uncertain whether intermittent/cyclic etidronate 400 mg/day changes withdrawals due to adverse events compared with placebo (very low certainty).

1 finding from 1 review

Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women 2024 · Cochrane Headline outcomes only
RR 1.09 [0.54, 2.18]
Studies not reported
Very low

Intermittent/cyclic etidronate 400 mg/day vs placebo

Withdrawals due to adverse events · postmenopausal women at lower risk of fractures1

Intermittent/cyclic etidronate 400 mg/day showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).

1 finding from 1 review

Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women 2024 · Cochrane Headline outcomes only
RR 1.41 [0.81, 2.47]
Studies not reported
Low

Risedronate 5 mg/day vs placebo

Withdrawals due to adverse events · pPostmenopausal women at higher risk of fractures1

Risedronate 5 mg/day showed no clear difference in withdrawals due to adverse events compared with placebo (high certainty).

1 finding from 1 review

Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women 2022 · Cochrane Headline outcomes only
RR 0.98 [0.9, 1.07]
Studies not reported
High

Risedronate 5 mg/day vs placebo

Withdrawals due to adverse events · postmenopausal women at lower risk of fractures1

Risedronate 5 mg/day showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).

1 finding from 1 review

Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women 2022 · Cochrane Headline outcomes only
RR 0.67 [0.38, 1.18]
Studies not reported
Low